Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–50
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Within body mass index (BMI) range 18 to 38 kilogram per meter square (kg/m2), inclusive. Body weight \<=100 kg
Left ventricular ejection fraction (LVEF) \>= 55 percent (%) measured by echocardiogram (ECHO)
Negative test result for drugs of abuse
Negative test result for hepatitis B surface antigen, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) antibody screen
Negative test for latent Tuberculosis (TB) infection by QuantiFERON® TB Gold
Agree to use contraception and will refrain from sperm donation
You may not be if
Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, respiratory, gastrointestinal, immunological, neurological, or psychiatric disorder; acute infection; or other unstable medical disease
History of moderate or severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins
Known sensitivity to recombinant hyaluronidase or other form of hyaluronidase
History or presence of atrial fibrillation
History of any clinically significant or clinically relevant cardiac condition
History or presence of clinically significant electrocardiogram (ECG) abnormalities
History of uncontrolled hypertension, hyperlipidemia, thyroid disorder, or diabetes
Family history of clinically significant and clinically relevant hypersensitivity, allergy, or severe cardiac diseases
History of previous anti-cancer treatments including pertuzumab, trastuzumab, anthracyclines, or any cardiotoxic drugs
History of active or latent TB, regardless of treatment history
Poor peripheral venous access
History or presence of any malignancy, with the exception of completely excised basal cell or squamous cell carcinoma of the skin
Clareo Health | A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
